ARTICLE | Product Development
Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors
June 16, 2020 1:03 AM UTC
With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in the human body within 10 years.
Formerly known as Elpis Biomed Ltd., Bit Bio Ltd.’s core technology is its opti-tox platform, which directly reprograms induced pluripotent stem (iPS) cells into specific cell types within days by enforcing expression of transcription factor combinations that determine cell fate. The idea is that the resulting cells could serve as the basis for specialized disease models or cell therapies (see “Total Reprogramming”)...
BCIQ Company Profiles